Resistance to glucocorticoids (GC) is an important adverse risk factor in the treatment of acute lymphoblastic leukemia (ALL). To induce apoptosis, GC bind to the GC receptor (GR), which is regulated by various (co)chaperone proteins such as heatshock protein 70 (HSP-70), HSP-40, HIP (HSP-70-interacting protein), BAG-1 (BCL-2-associated gene product-1), HOP (HSP-70/HSP-90-Organizing protein), HSP-90, P-23, FKBP-51, FKBP-52 and CYP-40. In this study, we tested the hypothesis that mRNA expression levels of these molecules are determinants of GC resistance in childhood ALL. In all, 20 children with ALL cells in vitro sensitive to prednisolone (LC 50 o0.1 lg/ml) were compared each with a resistant patient (LC 50 4150 lg/ml), matched for immunophenotype, age and white blood cell count. mRNA expression levels of the (co)chaperone molecules were measured by quantitative real-time RT-PCR and normalized to GAPDH and RNaseP levels. In vitro resistance to prednisolone was measured by MTT assay. HSP-90 mRNA expression levels were 2000-fold higher as compared to HSP-70. Using matched pair analysis, mRNA expression levels of the various (co)chaperone molecules were not significantly different between in vitro-sensitive and -resistant patients. GC resistance in childhood ALL cannot be attributed to different mRNA expression levels of the investigated (co)chaperone molecules involved in GC binding and transport to the nucleus.
Introduction
The glucocorticoids (GC) prednisone and dexamethasone have been used in the treatment of childhood acute lymphoblastic leukemia (ALL) for many decades. In vivo and in vitro response to GC are strong prognostic factors for clinical outcome, [1] [2] [3] but mechanisms underlying GC resistance in childhood ALL remain largely unknown. 4 After entering the cell by passive diffusion, GC bind to the glucocorticoid receptor (GR). Binding depends on the assembly of various (co)chaperone proteins within a GR-chaperone complex, which directs the GR to adopt a GC-binding conformation. The first step in this process is the binding of heat-shock protein 70 (HSP-70) and HSP-40 to the GR in an energy-dependent process, whereby BAG-1 (BCL-2-associated gene product-1) and HIP (HSP-70-interacting protein) can act as negative and positive regulators, respectively. 5 Secondly, HSP-90 and HOP (HSP-70/HSP-90 organizing protein) bind to this complex, leading to the opening of the GC-binding cleft of the GR in an ATP-dependent way. 5 This complex is stabilized by P-23
(protein 23) and several immunophillins like FKBP-51 (FK506-binding protein-51), FKBP-52 and CYP-40 (cyclophilin D) 5, 6 ( Figure 1 ). Upon binding, the GC-GR complex is transported to the nucleus, where it transactivates GC-responsive genes and/or transrepresses other transcription factors like AP-1 and NF-kB. For the transport of the GC-GR complex into the nucleus, (co)chaperone molecules like HSP-90 and FKBP-52 are suggested to be necessary for binding of the GC-GR complex to dynein, which is part of the microtubule-based movement machinery. 5, 7 FKBP-51 has an opposite effect, keeping the complex in the cytoplasm. 8 So far, only two (co)chaperone proteins have been studied in relation to GC resistance in ALL. Kojika et al 9 reported aberrant HSP-90 protein expression (80 and 160 kDa instead of 90 and 180 kDa) and extremely low HSP-70 protein expression in two out of nine resistant human leukemic cell lines. 9 In the only study using patient material, no relation was found between HSP-90 protein and mRNA expression, and in vivo GC sensitivity in children with ALL. 10 In the present study, we tested whether GC resistance in childhood ALL is associated with altered mRNA expression of the GR (co)chaperone molecules HSP-70, HSP-40, HIP, BAG-1, HOP, HSP-90, P-23, FKBP-51, FKBP-52 and CYP-40.
Materials and methods

Patients
In this case control study, 20 patients in vitro sensitive to prednisolone (LC 50 o0.1 mg/ml) were matched each to a patient in vitro resistant to prednisolone (LC 50 4150 mg/ml). Patients were matched for age (1-10 years or X10 years), immunophenotype (common-/pre-B-ALL or T-ALL) and white blood cell count (WBC, o50 000/ml or X50 000/ml) at diagnosis. Patient material was taken at diagnosis with informed consent from the patients or their parents.
The mononuclear cell fraction was separated by Lymphoprep density-gradient centrifugation (density 1.077 g/m 3 ; Nucomed Pharma, Oslo, Norway). When necessary, nonleukemic cells were depleted by immunomagnetic beads to purify the samples to more than 90% of blasts.
Isolation of RNA and cDNA synthesis
Total RNA was extracted using the Trizol method (Gibco BRL, Life Technologies, Breda, the Netherlands) according to the protocol provided by the manufacturer, with minor modifications. 11 RNA pellets were dissolved in 20 ml TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH ¼ 8.0), and quantified spectrophotometrically. cDNA was synthesized as described before, 11 diluted to a final concentration of 8 ng/ml and stored at À801C.
Quantitative real-time RT-PCR
mRNA levels of HSP-70, HSP-40, HIP, BAG-1, HOP, HSP-90, P-23, FKBP-51, FKBP-52, CYP-40 and GR-alpha (ie target PCRs) and two endogenous reference genes (ie GAPDH and RNaseP) were measured by quantitative real-time RT-PCR based on Taqman chemistry using an ABI PRISM 7700 sequence detector (Applied Biosystems, Foster City, CA, USA). PCR products were detected by a double-labeled, nonextendible probe containing a FAM reporter group and a TAMRA quencher group (Table 1) . 11 All primers and probes had melting temperatures of 65711C and 75711C, respectively (nearest-neighbor method 12 ). Genomic DNA (100 ng) served as a negative control and did not result in detectable amplification for any of these reactions, confirming the specificity of these reactions for RNA detection. In all, 40 ng of patient sample cDNA was amplified in duplo in the presence of 300 nM forward and reverse primers, 50 nM probe, 200 mM dNTPs, 4 mM MgCl 2 and 1.25 U of AmpliTaqt gold DNA polymerase in Taqman buffer A (Applied Biosystems) in a total volume of 50 ml. Samples were heated for 10 min at 951C and amplified in 40 cycles of 15 s at 951C and 60 s at 601C. A serial diluted positive control was amplified on each plate to verify the amplification efficiency within each experiment. 11 The average C t value was used to calculate the mRNA expression levels of the PCR targets relative to the expression level of the two housekeeping genes by the comparative C t method 12 using the equation
À½CtðtargetÞÀCtðreference geneÞ Â100
MTT assay
In vitro drug cytotoxicity was assessed using the MTT assay as described earlier. 2, 13 Briefly, patient blasts were cultured with or without prednisolone disodiumphosphate in a concentration range between 0.06 and 250 mg/ml. At day 4, MTT is added, which can only be reduced into formazan by viable cells. The reduced product was quantified spectrophotometrically at 562 nm. The leukemic cell survival was calculated by: (OD drug-treated well/OD control wells without drug) Â 100%. The LC 50 value represents the concentration of the drug at which 50% of the cells are killed and is used as a measure of in vitro drug cytotoxicity. Leukemic cells having LC 50 values lower than 0.1 mg/ml were assigned in vitro GC sensitive, and samples having LC 50 values exceeding 150 mg/ml were considered in vitro resistant, as previously described, to be of prognostic value.
13,14
Statistical methods
The nonparametric Wilcoxon signed-rank test for matched samples and the nonparametric Mann-Whitney U-test were used to analyze the results from the patient samples. A P-value p0.05 was considered statistically significant (two-tailed tested).
Results
In all, 40 patients were included in this case-control study. For each in vitro-sensitive patient, an in vitro-resistant control, matched for age, immunophenotype and WBC, was selected. Patient characteristics are depicted in Table 2 .
The expression levels of the different (co)chaperone molecules were measured by quantitative real-time RT-PCR. The PCR reactions were very specific, showing only one single PCR product of predicted size on gel ( Figure 2 ). Amplification efficiency was 95% or higher for all reactions (data not shown), which allows direct normalization of expression levels of each target PCR to the expression levels of the endogenous housekeeping genes GAPDH and RNaseP. Figure 3 shows the mRNA expression levels of the various (co)chaperone molecules relative to GAPDH for the whole study population. Compared to the other (co)chaperone molecules, the mRNA expression level of HSP-90 was relatively high, whereas the expression level of HSP-70 was relatively low, approximately 2000-fold lower than HSP-90. The median mRNA expression levels of the different (co)chaperone molecules and the GR for the in vitro-sensitive and -resistant patients are depicted in Table 3 .
Since we analyzed every GC-sensitive patient in relation to its matched control, the ratios of the mRNA expression levels of the various (co)chaperone molecules for each (Co)chaperone protein interactions with the GR. The stepwise assembly of the GR-(co)chaperone complex, leading to the opening of the GC-binding cleft and enabling GC binding. In a first, ATP-dependent step, HSP-70 and HSP-40 bind to the GR. This step is inhibited by BAG-1 and activated by HIP. Hereafter, HOP and HSP-90 bind to the GR, which opens, in an ATP-dependent step, the GC-binding cleft, enabling the GR to bind GC. This complex is stabilized by P-23 and the immunophilins FKBP-51, FKBP-52 and CYP-40. One of the models hypothesized in the literature is that FKBP-52 promotes binding of the GC-GR complex to dyneins for transportation into the nucleus, whereas FKBP-51 promotes retainment of the complex in the cytoplasm.
prednisolone-sensitive case relative to its matched prednisolone-resistant control case were calculated and shown in Figure 4 . The median ratio was about 1 for each of the (co)chaperone molecules. Using matched-pair analysis, no differences in expression for any of these molecules were found between in vitro-sensitive and -resistant patients. Normalization to RNaseP instead of GAPDH led to the same conclusions (data not shown).
With BAG-1 being an inhibitor of HSP-70 and HIP being a positive regulator, the ratio of these two chaperone molecules was determined and related to GC sensitivity. No difference was found between the matched in vitro-sensitive and -resistant patients with respect to the ratio of the mRNA expression levels of BAG-1 and HIP (Figure 5a ). Table 1 Primer GenBank accession codes used for designing the primers and probes are depicted. As FKBP-51 and FKBP-52 might compete for binding to the GR complex, thereby affecting the nuclear shuffling of the GC-GR complex, the ratio of these molecules was calculated and related to GC sensitivity. No difference for the FKBP-51/ FKBP-52 mRNA ratio was found between the matched in vitro prednisolone-sensitive and -resistant patients (Figure 5b ).
Since HSP-90 has been reported to be involved in the stabilization of the GC-GR complex binding to the promotor of GR-responsive genes while P-23 has the opposite effect, the ratio of the mRNA expression levels of these molecules was studied in relation to GC resistance. However, we did not find any difference between sensitive and resistant patients (Figure 5c ). The ratio of HSP-90 and the functional GR (GRalpha) mRNA levels might be related to GC resistance as well. We were able to calculate an HSP-90/GR-alpha ratio in 12 matched patient samples. No relation was found between this ratio and GC resistance (Figure 5d ).
Discussion
GC enter the cell by passive diffusion to bind the GR. To enable binding, the GR undergoes a stepwise maturation process in which it is bound by various (co)chaperone proteins, eventually leading to the opening of the GC-binding pocket (Figure 1 ). 5 Which of the proteins are absolutely necessary for this process remain unclear. Some reports state that only HSP-90 and HSP-70 are minimally required, 15 but most studies report the necessity of at least five proteins (HSP-90, HSP-70, HSP-40, HOP and P-23). 16, 17 In the present case-control study, we analyzed the mRNA expression levels of the (co)chaperone proteins of the GR in relation to GC resistance in childhood ALL. The chaperone molecule HSP-70 had a relatively low mRNA expression level, while the mRNA expression level of HSP-90 was relatively high (2000-fold higher than HSP-70 expression), which is in concordance with earlier studies reporting protein and mRNA levels of HSP-90 and HSP-70 in acute leukemias. 10, 18, 19 As HSP-70 is part of the more immature GR-(co)chaperone complex, its low expression level might determine a ratelimiting step in the initial maturation process of the GR. For none of the (co)chaperone molecules as tested in this study, a relation between mRNA expression level and in vitro GC resistance was found.
We tested different other hypotheses on a possible relation between GR (co)chaperone expression and GC resistance. The ratio of BAG-1, which is a negative regulator of HSP-70 20 and HIP, which is a positive regulator, might be correlated to GC Figure 2 PCR products of the (co)chaperone molecules. Example of real-time RT-PCR products resolved on agarose gel for the various target genes as tested in this study, to show that the PCR reactions are very specific, resulting in only one PCR product per reaction.
Figure 3
Expression levels of (co)chaperone molecules in pediatric ALL cells. mRNA expression levels, relative to GAPDH, of all study patients are depicted. Lines indicate the median values. Table 3 mRNA expression levels of the different (co)chaperone molecules and the GR receptor relative to GAPDH for the in vitrosensitive and -resistant patients resistance. 21 However, such a correlation was not found in our study population. BAG-1 is also reported to be an inhibitor of DNA binding and subsequent transcriptional activation by the GR, 22 but we did not find a relation between BAG-1 mRNA expression levels and GC resistance either.
For transportation of the GC-GR (co)chaperone complex to the nucleus, FKBP-51 is replaced by FKBP-52 in this complex. Some New World primate genera are very resistant to GC. In these animals, it was shown that an elevated protein expression of FKBP-51 contributed to GC resistance. 23 Studies analyzing protein expression levels showed that FKBP-52 potentiates reporter gene activation, which is attenuated by FKBP-51. 8, 24 We hypothesized that the ratio of FKBP-51 and FKBP-52 mRNA levels is related to GC resistance. As we could not show such a correlation in our study population, and as we did not show a relation between FKBP-51 mRNA expression and GC resistance either, the relevance of FKBP-51 for GC resistance as found in some New World primates cannot be extrapolated to GC resistance in childhood ALL.
HSP-90 stabilizes the binding of the GC-GR complex to the promotor of GR-responsive genes, while P-23 induces removal of this complex from the promotor. 25 Longer GR residence time at these promotor sites is associated with greater transcriptional output, so expression of HSP-90 and P-23 might be related to GC resistance. By studying the ratio of HSP-90 and P-23 mRNA expression levels and GC resistance, we conclude that this ratio is not correlated to GC resistance in childhood ALL. Another study reported a negative effect of HSP-90 protein levels on GR function when the ratio HSP-90/GR increased. 26 No such negative effect of mRNA expression levels was found in our patient cohort.
The conclusion of an earlier study, that HSP-90 expression levels are not related to GC resistance, 10 is confirmed in this (larger) study, and we show that the mRNA expression levels of other (co)chaperone molecules of the GR are not related to GC resistance as well. It might be that not mRNA levels, but protein levels of the different (co)chaperone molecules are correlated with GC resistance (ie post-transcriptional regulation instead of transcriptional regulation). However, a correlation between mRNA and protein levels has been shown previously for HSP-90, HSP-70, BAG-1, FKBP-51 and FKBP-52 in different cell lines. [27] [28] [29] [30] [31] Owing to the limitation of patient material, it was not possible to confirm these data in our population. Another hypothesis relating (co)chaperone molecules to GC resistance might be that not the expression level but rather the functional capacity of the (co)chaperone molecules to form a complex with the GR instead of the expression level of the (co)chaperone molecules is related to GC resistance. This complex formation process might, for example, be influenced by mutations in one of the genes encoding for the (co)chaperone proteins. When one step of the maturation process of the GR is disturbed, GC binding might decrease, resulting in reduced transactivation or transrepression of GC-responsive genes. Using dexamethasone binding assays, it was shown that decreased binding of dexamethasone was related to GC resistance in childhood ALL. Although this finding was regarded to be due to a lower expression level of the GR, 32 it may alternatively be related to a reduced rate in complex maturation due to defects in one of these molecules other than just the expression level of these molecules. However, to study the formation of the GR-(co)chaperone complex will be very difficult when using patient material, as the different stages of this complex will pass quickly. A last hypothesis on the relevance of the (co)chaperone expression for GC sensitivity might be that not the expression level before start of therapy, but the (co)chaperone expression level upon GC exposure is related to GC sensitivity and resistance. In this sense, it is of interest that, using microarray studies, one of the genes found to be upregulated upon GC exposure is FKBP-51. 33 However, till date there are no data on differences in gene expression upon GC exposure between GC-sensitive and -resistant ALL cells. Ratio of the (co)chaperone mRNA expression levels of the matched prednisolone-sensitive and -resistant ALL patients. Distribution of the ratio of the (co)chaperone molecules for the matched prednisolone-sensitive and -resistant patients. mRNA expression levels, relative to GAPDH, were used for the calculation of the ratio. Lines indicate the median values.
In conclusion, childhood ALL cells have a relatively high mRNA expression level of HSP-90 and a low expression level of HSP-70. The expression levels of the different (co)chaperone molecules of the GR are not related to GC resistance. 
